Zydus Lifesciences gains on getting USFDA`s approval for 'Dapagliflozin Tablets'
Zydus Lifesciences is currently trading at Rs. 884.35, up by 10.70 points or 1.22% from its previous closing of Rs. 873.65 on the BSE.
The scrip opened at Rs. 910.80 and has touched a high and low of Rs. 910.80 and Rs. 879.90 respectively. So far 29876 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 813.00 on 16-Apr-2025.
Last one week high and low of the scrip stood at Rs. 910.80 and Rs. 835.85 respectively. The current market cap of the company is Rs. 89,112.08 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has secured final approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga Tablets, 5 mg and 10 mg). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
With this approval, the company is eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets, 5 mg and 10 mg. Dapagliflozin tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 436 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.
